CLINICAL TRIALS PROFILE FOR ZANUBRUTINIB

All Clinical Trials for ZANUBRUTINIB

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT02569476 ↗	BGB 3111 in Combination With Obinutuzumab in Participants With B-Cell Lymphoid Malignancies	Completed	BeiGene	Phase 1	2016-01-13	This study evaluated the safety and preliminary efficacy of BGB-3111 (zanubrutinib) in combination with obinutuzumab in participants with B-cell lymphoid malignancies.
NCT02795182 ↗	Zanubrutinib (BGB-3111) in Combination With Tislelizumab (BGB-A317) in Participants With B-cell Malignancies	Completed	BeiGene	Phase 1	2016-06-29	This study is evaluating the safety and preliminary efficacy of BGB-3111 in combination with BGB-A317 in participants with B-cell lymphoid malignancies.
NCT02914938 ↗	A Study of ME-401 in Subjects With CLL/SLL, FL, and B-cell Non Hodgkin's Lymphoma	Recruiting	Clinipace LTD	Phase 1	2016-10-01	A Three-Arm Study of ME-401 in Subjects with Relapsed/Refractory CLL/SLL or FL, of ME-401 in Combination with Rituximab in Subjects with Relapsed/Refractory CLL/SLL or B-cell NHL, and of ME-401 in Combination with Zanubrutinib in Subjects with Relapsed/Refractory CLL/SLL or B-cell NHL
NCT02914938 ↗	A Study of ME-401 in Subjects With CLL/SLL, FL, and B-cell Non Hodgkin's Lymphoma	Recruiting	MEI Pharma, Inc.	Phase 1	2016-10-01	A Three-Arm Study of ME-401 in Subjects with Relapsed/Refractory CLL/SLL or FL, of ME-401 in Combination with Rituximab in Subjects with Relapsed/Refractory CLL/SLL or B-cell NHL, and of ME-401 in Combination with Zanubrutinib in Subjects with Relapsed/Refractory CLL/SLL or B-cell NHL
NCT03053440 ↗	A Study Comparing BGB-3111 and Ibrutinib in Participants With Waldenström's Macroglobulinemia (WM)	Active, not recruiting	BeiGene	Phase 3	2017-01-25	This study is to evaluate the safety, efficacy and clinical benefit of BGB-3111 (Zanubrutinib) vs ibrutinib in participants with MYD88 Mutation Waldenström's Macroglobulinemia.
NCT03088878 ↗	A Study of Cirmtuzumab and Ibrutinib in Patients With B-Cell Lymphoid Malignancies	Recruiting	California Institute for Regenerative Medicine (CIRM)	Phase 1/Phase 2	2018-01-03	This is Phase 1b/2 study to investigate the safety and effectiveness of the investigational drug, cirmtuzumab, when given in combination with ibrutinib in patients with B-cell lymphoid malignancies. Cirmtuzumab is a monoclonal antibody that attaches to a protein (called ROR 1) that is found on hematologic tumor cells. ROR1 has been shown to play a role in cell signaling that cause leukemia and lymphoma cells to grow and survive. ROR1 is rarely found on healthy cells.
NCT03088878 ↗	A Study of Cirmtuzumab and Ibrutinib in Patients With B-Cell Lymphoid Malignancies	Recruiting	Oncternal Therapeutics, Inc	Phase 1/Phase 2	2018-01-03	This is Phase 1b/2 study to investigate the safety and effectiveness of the investigational drug, cirmtuzumab, when given in combination with ibrutinib in patients with B-cell lymphoid malignancies. Cirmtuzumab is a monoclonal antibody that attaches to a protein (called ROR 1) that is found on hematologic tumor cells. ROR1 has been shown to play a role in cell signaling that cause leukemia and lymphoma cells to grow and survive. ROR1 is rarely found on healthy cells.

Clinical Trial Conditions for ZANUBRUTINIB

Condition Name

Condition Name for ZANUBRUTINIB
Intervention	Trials
Chronic Lymphocytic Leukemia	23
Mantle Cell Lymphoma	19
Small Lymphocytic Lymphoma	17
Diffuse Large B Cell Lymphoma	12

Condition MeSH

Condition MeSH for ZANUBRUTINIB
Intervention	Trials
Lymphoma	59
Lymphoma, Large B-Cell, Diffuse	39
Leukemia, Lymphocytic, Chronic, B-Cell	36
Lymphoma, B-Cell	32

Clinical Trial Locations for ZANUBRUTINIB

Trials by Country

Trials by Country for ZANUBRUTINIB
Location	Trials
United States	277
China	212
Australia	74
Japan	33
France	22

Trials by US State

Trials by US State for ZANUBRUTINIB
Location	Trials
Florida	19
Texas	18
New York	18
California	16
Massachusetts	15

Clinical Trial Progress for ZANUBRUTINIB

Clinical Trial Phase

Clinical Trial Phase for ZANUBRUTINIB
Clinical Trial Phase	Trials
PHASE4	2
PHASE3	4
PHASE2	56

Clinical Trial Status

Clinical Trial Status for ZANUBRUTINIB
Clinical Trial Phase	Trials
RECRUITING	87
NOT_YET_RECRUITING	35
Not yet recruiting	30

Clinical Trial Sponsors for ZANUBRUTINIB

Sponsor Name

Sponsor Name for ZANUBRUTINIB
Sponsor	Trials
BeiGene	55
Ruijin Hospital	12
Institute of Hematology & Blood Diseases Hospital, China	9

Sponsor Type

Sponsor Type for ZANUBRUTINIB
Sponsor	Trials
Other	159
Industry	79
NIH	9

Clinical Trials Update, Market Analysis, and Projection for Zanubrutinib

Last updated: January 27, 2026

Summary

Zanubrutinib (trade name Brukinsa) is a Bruton’s tyrosine kinase (BTK) inhibitor developed by BeiGene. Approved in the U.S. in 2019 for mantle cell lymphoma (MCL), it has gained regulatory approval for multiple hematological malignancies. This analysis reviews recent clinical trial developments, evaluates current market landscape, and projects future growth based on ongoing research, regulatory trends, and competitive positioning.

---

What Are the Recent Updates in Clinical Trials for Zanubrutinib?

Overview of Clinical Trial Phases and Key Studies

Phase	Key Trials	Status	Focus	Participants	Results/Findings
Phase 1/2	BGB-3111-214 (ASPEN Study)	Completed	Waldenström macroglobulinemia (WM), MCL	150+	Superior efficacy over ibrutinib in WM; favorable safety profile
Phase 3	ASPEN (NCT04033349)	Ongoing	WM	Approx. 260	Comparing Zanubrutinib vs. Ibrutinib; primary endpoint PFS ongoing
Phase 3	MAGNOLIA (NCT03846427)	Ongoing	Marginal zone lymphoma (MZL)	~240	Efficacy and safety data expected 2023-2024
Phase 2	ALPINE (NCT03734016)	Recruiting	Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)	~300	Direct comparison with ibrutinib; primary endpoints PFS, ORR
Phase 2	BGB-3111-AU-003	Completed	CLL/SLL in Australia	100	Promising early efficacy signals

Recent Clinical Data Highlights

• Waldenström Macroglobulinemia (WM): The ASPEN trial demonstrated Zanubrutinib’s superior efficacy and safety, with a 78% overall response rate, compared to 68% with ibrutinib (p=0.045). Notably, lower atrial fibrillation incidence compared to ibrutinib.

• Mantle Cell Lymphoma (MCL): In pivotal trials, Zanubrutinib showed high overall response rates (~84%) with durable remissions, comparable to other BTK inhibitors.

• Chronic Lymphocytic Leukemia (CLL): Early data from ongoing trials indicate promising progression-free survival (PFS) and manageable adverse events, with ongoing head-to-head comparisons with ibrutinib.

Regulatory and Market-Related Updates

• FDA Approvals: Originally approved in 2019, subsequent approvals based on data from trials such as MAGNOLIA (for MZL) are anticipated by late 2023.

• Global Access: BeiGene has successfully obtained regulatory approvals in China, the U.S., and several European countries; expansion plans focus on Latin America, Asia-Pacific, and Middle East regions.

---

What Is the Current Market Landscape for Zanubrutinib?

Market Overview and Competitive Position

Company	Product Name	Market Launch	Indications	Global Revenue (2022)	Market Share (Hem. Malignancies)	Key Competitors
BeiGene	Zanubrutinib (Brukinsa)	2019 (US/China)	MCL, WM, MZL, CLL	$1.2 billion	~20% in BTK inhibitor class	Ibrutinib (Imbruvica), Acalabrutinib (Calquence)
Janssen	Ibrutinib (Imbruvica)	2013	Multiple B-cell malignancies	$7 billion	Dominant (~50%)	N/A
AstraZeneca	Acalabrutinib (Calquence)	2019	CLL, MCL	$1.1 billion	Growing	Ibrutinib, Zanubrutinib

Market Drivers

• Efficacy & Safety Profile: Zanubrutinib’s lower rates of atrial fibrillation and bleeding favor regulatory and clinician uptake.

• Expanding Indications: Clinical success in WM, MZL, and CLL broadens its market scope.

• Pricing & Reimbursement: BeiGene adopts aggressive pricing strategies, aiming for wider reimbursement approvals, especially in China and emerging markets.

Market Challenges

• Competitive Landscape: Ibrutinib remains dominant; Acalabrutinib gaining share.

• Patent and Exclusivity: Patent protections extend until 2028-2030 in major markets; biosimilar threats possible post-expiry.

• Clinical Data: Long-term comparative data remain limited, impacting prescribing confidence.

---

What Are the Future Growth Projections for Zanubrutinib?

Forecast Models and Assumptions

Parameter	Assumptions	Impact	Projection (2023-2028)
Number of Patients	CAGR of 12% in treated population (global B-cell malignancies)	Increased adoption	15,000+ patients globally in 2028
Regulatory Approvals	Additional approvals in Asia, Europe, and emerging markets	Market penetration	+35% market expansion
Clinical Trials Success	Positive data leading to new indications (e.g., CLL, MZL)	Indication breadth	3-4 new approved uses by 2026
Competitive Dynamics	Slight erosion of market share due to biosimilars or competitor drugs	Market share adjustment	15-20% share in BTK inhibitor class by 2028
Pricing Strategy	Maintains premium positioning with volume growth	Revenue growth	$2.5–3.2 billion in 2028

Projected Revenue in Global Hematologic Malignancy Market

Year	Estimated Revenue	CAGR	Notes
2023	$1.2 billion	—	Current baseline
2024	$1.7 billion	41%	Expanded approvals, new trial data
2025	$2.2 billion	29%	New indications, increased market penetration
2026	$2.8 billion	27%	Additional approvals in Europe, Asia
2027	$3.4 billion	21%	Increased adoption, competitive responses
2028	$3.9 billion	15%	Maturation of indications; competition impacts

---

Comparison Summary: Zanubrutinib Versus Key Competitors

Aspect	Zanubrutinib	Ibrutinib	Acalabrutinib
Approval Year	2019	2013	2019
Mechanism	Covalent BTK inhibition	Covalent BTK inhibition	Covalent BTK inhibition
Dosing Regimen	Once daily	Once daily	Twice daily
Safety Profile	Lower atrial fibrillation (16%)	Higher atrial fibrillation (22%)	Similar to Zanubrutinib but data limited
Efficacy (WM & MCL)	Comparable or superior	Established	Comparable but less data

---

Questions & Answers

1. What are the primary indications approved for Zanubrutinib?

• Mantle cell lymphoma (MCL)
• Waldenström macroglobulinemia (WM)
• Marginal zone lymphoma (MZL) (pending additional approvals)
• Chronic lymphocytic leukemia (CLL)/SLL (pending further approval)

2. How does Zanubrutinib compare to ibrutinib in terms of efficacy and safety?

• Efficacy in WM and MCL is comparable; in some cases, superior (e.g., higher ORR in WM).
• Safety profile favors Zanubrutinib, with fewer cardiovascular adverse events such as atrial fibrillation (~16% vs. 22%).
• Better tolerability may drive off-label use and combination therapy considerations.

3. What factors could influence Zanubrutinib’s market growth over the next five years?

• Regulatory approval in additional jurisdictions.
• Results of ongoing head-to-head trials (e.g., ALPINE).
• Broader adoption driven by improved safety profile.
• Competitive dynamics, including biosimilars and new BTK inhibitors.
• Price strategies and reimbursement policies.

4. What are the key challenges facing Zanubrutinib’s market expansion?

• Competitive pressure from established BTK inhibitors.
• Long-term safety and efficacy data—particularly durability of responses.
• Patent expiries and biosimilar threats post-2028.
• Manufacturing constraints and supply chain complexities.

5. How is BeiGene positioning Zanubrutinib globally?

• Aggressive pricing in China, U.S., and emerging markets.
• Rapid expansion through regulatory filings and clinical data.
• Focused on differentiating via safety profile rather than just efficacy.
• Partnership and licensing agreements to accelerate market reach.

---

Key Takeaways

• Regulatory momentum and strong clinical data position Zanubrutinib for continued growth, particularly in WM and MCL settings.
• Clinical trial results favor safety, offering potential advantages over competitors.
• Market expansion relies on approval of new indications and geographic reach, especially in Europe and Asia-Pacific.
• Competitive dynamics will challenge Zanubrutinib’s market share; differentiation will hinge on safety and long-term efficacy data.
• Projected revenues could reach nearly $4 billion globally by 2028, contingent on trial outcomes, regulatory approvals, and market penetration strategies.

---

References

1. BeiGene. (2022). Brukinsa (Zanubrutinib) Prescribing Information.
2. U.S. Food and Drug Administration. (2019). FDA approves Brukinsa for mantle cell lymphoma.
3. ClinicalTrials.gov. (2023). Various ongoing Zanubrutinib trials (e.g., NCT04033349, NCT03734016).
4. GlobalData Healthcare. (2022). Hematology market analytics report.
5. EvaluatePharma. (2022). Oncology drug revenue forecast.

---

Note: The market and clinical data reflect available information up to Q1 2023 and are subject to change with new trial outcomes or regulatory decisions.